<u>PATENT</u> Docket No. 112917-143

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Jacques F. Banchereau et al.

U.S. Serial No.:

10/042,644

RECEIVED

Filing Date:

January 8, 2002

JAN 03 2003

Group Art Unit:

1646

TECH CENTER 1600/2900

Examiner:

Not Yet Known

For:

Methods For Treating Autoimmune Diseases In A Subject And In Vitro Diagnostic Assays

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope with sufficient postage in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

Date

Nancy E. Gilmore

TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed are the following for appropriate action:

- 1. Supplemental Information Disclosure Statement;
- 2. PTO-1449 and copies of 7 references cited therein; and
- Return Postcard.


Respectfully submitted,

Date: 12/23/02

Jane M. Love, Ph.D. Registration No. 42,812 Attorney for Applicant

HALE AND DORR LLP 300 Park Avenue New York, New York 10022 (212) 937-7233 (telephone) (212) 937-7300 (facsimile)

Supplemental IDS Applicant: Jacques F. Banchereau et al. U.S. Serial No.: 10/042,644 Filed: January 8, 2002 NEWYORK 59035v1





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Jacques F. Banchereau et al.

U.S. Serial No.:

10/042,644

Filing Date:

January 8, 2002

Group Art Unit:

1646

Examiner:

Not Yet Known

For:

Methods For Treating Autoimmune Diseases In A Subject

And In Vitro Diagnostic Assays

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope with sufficient postage in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

23,2002

Date

Nancy E. Gilmore

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the attention of the Examiner the following documents listed on the attached PTO Form 1449. This Information Disclosure Statement is being filed before the mailing date of any first Office Action on the merits, and is therefore submitted as both timely and proper.

Supplemental IDS Applicant: Jacques F. Banchereau et al. U.S. Serial No.: 10/042,644 Filed: January 8, 2002 Applicants state that the documents listed on the attached PTO Form 1449 were cited in

an International Search Report issued in connection with related Patent Cooperation Treaty

application number PCT/US02/00343. It is respectfully requested that the Examiner initial and

return a copy of the enclosed PTO Form 1449 with the next Patent Office communication.

If a telephone interview would be of assistance in advancing prosecution of the subject

application, applicants' undersigned attorney invites the Examiner to telephone at the number

provided below.

No fees are believed to be due in connection with the filing of this Information

Disclosure Statement. However, the Commissioner is authorized to debit any necessary fee or

credit any overpayment relating to this application to Deposit Account No. 08-0219.

Respectfully submitted,

Janem Lone

Jane M. Love, Ph.D.

Reg. No. 42,812

Attorney for Applicants

HALE AND DORR LLP 300 Park Avenue

New York, NY 10022 Direct No. (212) 937-7233

Telephone (212) 937-7200

Fax: (212) 937-7300

Supplemental IDS

Applicant: Jacques F. Banchereau et al.

2



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

		_
Complete if Known		
Application Number	10/042,644	
Filing Date	1/8/02	
First Named Inventor	Banchereau et al.	
Art Unit	1646	
Examiner Name	Not Yet Known	
Attorney Docket Number	112917-149	

		Page 1	of 2			
				U.S. PATE	NT DOCUMENTS	
Examiner Initials	Cite No.	Document Number-Kind Co		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		5,888	,511	3/30/99	Skurkovich et al.	
		5,889	,151	3/30/99	Mogensen et al.	
		5,919	,452	7/6/99	Le et al.	
						FINED
					,	DECEI
						PECENED JAN 0 3 2003 TECH CENTER 16001290
						LAN 0 3 2 MAN
						3. 16001C
	,					CENTER
			·			TEUT
				_		
	ļ.					

		FOREIGN F	ATENT DO	CUMENTS		
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
		EP 0 627 487 A2	7/12/97	EUROPE		

Examiner	Date	
Signature	Considered	



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known		
Applicati n Number	10/042,644	\neg
Filing Date	1/8/02	
First Named Inventor	Banchereau et al.	
Art Unit	1646	
Examiner Name	Not Yet Known	
Attorney Docket Number	112917-149	

Page of 2 OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Examiner Cite No. Huang, Xiaojian et al. Islet Expression of Interferon-α Precedes Diabetes in both the BB Rat and Streptozotocin-Treated Mice. Immunity 1:469-478 а (1994).Soos, Jeanne M. et al. Oral feeding of interferon T can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. b Journal of Neuroimmunology 75:43-50 (1997). PCT Notification of Transmittal of International Search Report or The С Declaration for PCT/US02/00343, dated December 4, 2002. RECEIVED

JAN 0 3 1003

TECHCENTER 1600/200

$\overline{}$	
1	
Examiner	Date
Cignoturo	Considered
Signature	Considered